Britain and America have signed a major bilateral deal that will keep no import taxes on UK medicine products being sold in the American market.
Key Provisions of the Pact
Under the terms of the agreement, the UK has committed to increase funding on pharmaceuticals through the NHS. This commitment ensures that duties on these key goods will remain at zero for a timeframe of three years.
This development follows previous warnings to hike import taxes on branded drug imports, with potential rates floated as high as double the cost.
"This arrangement between the United Kingdom strengthens the worldwide climate for cutting-edge drugs and establishes long-overdue fairness to U.S.–U.K. pharmaceutical trade," an announcement declared.
Trade Importance
Medicines are one of the Britain's largest export categories to the America, which is by far the largest buyer for large British pharmaceutical firms.
Export figures indicate that in the 12 months leading up to the third quarter, the UK exported medicines valued at £11.1bn to the US. This amount represented 17.4% of all goods exports in that span.
"This guarantee safeguards jobs, increases funding and paves the way for the UK to become a worldwide center for biotech and pharma," the Business and Trade Secretary commented.
Key NHS Changes
The pact entails several notable pledges from the United Kingdom:
- Revised Affordability Limit: The UK will raise the affordability limit at which it deems new treatments to be prohibitively costly by a quarter.
- Higher Drug Budget: There is a aim to double total health service expenditure on treatments from 0.3 percent of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Rebate Cap: The amount manufacturers must pay back to the NHS to control costs will be capped at fifteen percent. Last year, repayments exceeded 20%.
Broader Context
This agreement follows a protracted tension between the drug companies and the ministers over spending levels and NHS adoption.
These tensions were heightened by assertions that US customers were charged a premium for the equivalent treatments than people in the other developed nations.
Over the last 18 months, several major pharmaceutical investments in the UK have been delayed or cancelled, while multi-billion-dollar funding commitments have been announced toward American operations.
One official stated that the NHS must invest a greater share on medicines, noting that its spending on drugs had declined as a proportion of its overall budget over the previous ten-year period.
